Compare Alcon AG (ALC) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Vanguard Value Index Fund ETF — how do they compare? Alcon AG trades at $72.5 (market cap $36.44B), while Vanguard Value Index Fund ETF trades at $225.57. The key difference: Alcon AG pays a 0.48% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | VTV | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | — |
52-Week High | $90.12 | $225.35 |
52-Week Low | $62.02 | $179.43 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
VTV trades at $225.71, up 0.31% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced exposure. A dividend of $1.08 is scheduled for June 2026, adding income appeal.
The value rotation narrative supports VTV's momentum, though RSI levels indicate potential near-term overbought conditions. Risks include sector concentration and market volatility. Analyst sentiment remains positive given the ETF's diversification and current market trends favoring value strategies over tech-heavy indexes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
